Based on our Dispersome® technology platform, we can offer various opportunities for partnerships with both biotech and pharma companies.
ZERION has established a strong intellectual property position where it is possible to offer exclusivity for a Dispersome® drug formulation until 2040. Our proprietary technology platform is easy to adopt and does not require investment in new and specialized equipment.
ZERION has a number of ongoing, undisclosed partnerships with established pharmaceutical companies. These are focused on improving drug solubility and bioavailability of completely novel drug compounds. The typical partnership program progresses through a feasibility phase of 2-4 months duration into a more committing program. We have established a very easy and cost-effective feasibility program where the feasibility of using the Dispersome® technology is tested on one or more partner compounds. Please contact us for more information about this program.
Additionally, we are seeking partners that are interested in the distribution of our own proprietary drug formulations, or alternatively in co-development programs. Should you be interested in learning more about our internal pipeline and other partnering opportunities, please contact us for more information.
Zerion Pharma and Hovione have teamed up and are offering potential pharma partners an end-to-end development process for Dispersome®-based formulations with capability for scale up and GMP manufacturing. The Dispersome® technology can be applied at any stage of drug discovery or drug development including in preclinical studies, first in man and replacement of existing drug formulations. By combining forces Zerion and Hovione will enable access to an innovative drug delivery platform and world class expertise in development and manufacturing, with the shortest possible development time.
Dispersome® is a solubility enhancement technology that relies on an innovative and naturally occurring excipient to develop amorphous solid dispersions with high drug loading and high bioavailability.
Zerion Pharma and Hovione are offering pharma and biotech companies worldwide access to an innovative drug delivery platform combined with an unparalleled experience in development, scale up and GMP manufacturing. This unique combination provides customers with a line of sight over the entire development life cycle of oral solid dosage forms from API to commercial drug product.
